Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of Vera Therapeutics (NasdaqGM:VERA) with a ...

Wolfe Research initiated coverage of Vera Therapeutics (VERA) with an Outperform rating and $49 price target The firm is ...

Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent ...

Goldman Sachs has initiated coverage of Vera Therapeutics (VERA) with a buy rating, citing its drug candidate atacicept and a ...

Analyst Farzin Haque of Jefferies maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of $58.00.Invest ...

Shares of NASDAQ VERA opened at $37.48 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The company has a 50 day simple moving ...

Read Our Latest Analysis on VERA Vera Therapeutics Stock Down 0.5 % The company has a market capitalization of $2.19 billion, a P/E ratio of -13.25 and a beta of 1.15. The company has a debt-to ...

Vera Therapeutics BRISBANE, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on January 8, 2025, the Compensation Committee granted inducement ...

Check the time stamp on this data. Updated AI-Generated Signals for Vera Therapeutics Inc. (VERA) available here: VERA. Type ...

Vera Therapeutics BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing ...

Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...

BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative ...